JNJ vs TEM

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Tempus AI Inc. continues to operate in the high-growth, AI-driven precision medicine sector with a vast TAM and a strong strategic vision, bolstered by its proprietary multi-modal data library and recent acquisitions like Ambry. Q1 2026 earnings showed a revenue beat and strong gross margin expansion (63.8%), with exceptional MRD volume growth (+500% YoY), affirming its market position. However, s...